Disease guides
Our team prepared a quick overview of the most prevalent health issues. As a result, disease outlook, diagnosis, standard therapy, new treatment solutions and statistics are structured in one place.
Articles
Quick informational support on hot topics.
Disease guides
An intuitive map on the most current health issues.
Treatment guides
The latest treatment approaches in one place.
Parotid (Salivary) Gland Cancer Guide
About 80% of all salivary gland tumors are in the parotid gland. 12% of all cases of oral and pharyngeal cancer are related to the parotid gland. Parotid gland cancer develops simultaneously from both sides of the face in 10-15% of cases. About 80% of all parotid tumors are benign.
Neurofibromatosis (NF) Guide
About 96% of all confirmed neurofibromatosis cases worldwide are represented by neurofibromatosis type 1. On average, only one human out of 25,000 got a neurofibromatosis type 2. About 0,3% of affected patients are not developing a single symptom but still can pass this condition to their offspring.
Thymus Cancer Guide
In the USA, only about 390 new cases of thymus cancer are discovered yearly. Every two in three patients with thymus cancer are asymptomatic when diagnosed. Patients with thymus cancer have 28% more chances of developing other types of cancer. Thymus cancer represents 20% of all tumors in the mediastinum.
Gallbladder Cancer Guide
Up to 85% of patients with gallbladder cancer also have gallstones. About 4 000 new cases of gallbladder cancer are verified yearly in the USA. Gallbladder tumors represent up to 80-95%of all hepatic-biliary tract cancers. Only 30% of patients receive a diagnosis of gallbladder cancer before surgery.
Chiari Malformation Guide
About 90% of patients with Chiari malformation type 1 don't show specific symptoms. 80% of adult patients with newly discovered CM are women. About 50% of all Chiari malformation type 1 discovering incidentally. Up to 18% of kids with Chiari malformation type 2 die before age three.
Neuroendocrine (NETs) Tumors Guide
Only about 0,5% of newly diagnosed cancers are neuroendocrine tumors. 12-22% of patients with newly diagnosed neuroendocrine tumors already have metastases. The prevalence of neuroendocrine tumors in the USA is only 103,312 cases. There are 2,5 times more female patients with neuroendocrine tumors than male patients.